Pre-Conference Focus Day
Tuesday June 21, 2022
All times in EDT
9:50 am Chair’s Opening Comments
10:00 am Immune Disease Panel Discussion – Developing Microbiome-Specific Translational Models
10:30 am Competitive Positioning of Microbiome-based Therapeutics within the IBD Landscape
Synopsis
- Critical unmet patient needs in IBD
- Overview of the broader competitive landscape for therapeutics for inflammatory bowel diseases
- Opportunities for differentiated microbiome-based therapeutics and precision medicine approaches in IBD
11:00 am Morning Refreshments
11:30 am Human Microbial Lectins
Synopsis
- Understanding the role of lectins in host-microbe interactions
- Human microbial lectins are abundant, diverse and almost completely uncharacterized
- Human microbial lectins have the potential to be developed into novel therapeutics
12:00 pm Development and Manufacturing of Synthetic Biology-Based Microbiome Immunotherapies
Synopsis
- Modulating the immune response by leveraging the microbiome-host interaction
- Highlight critical steps in developing novel synthetic biology-based microbiome drugs
- Transitioning a microbiome product from pre-clinical to clinical stage
12:30 pm
Morning Immune Disease Deep Dive Round Table Discussions
1:00 pm
Refreshments & Networking Opportunities
2:00 pm Ancillary Clinical benefits of SER-109 in patients with CDI: Beyond recurrence
2:30 pm Unlocking Access to Secondary Metabolites through Cell-free Systems
Synopsis
- How to scale up a cell-free approach to expressing novel chemicals
- What cell-free systems could mean for the gut microbiome field
- Summary of comparable approaches and why cell-free stands to win
3:00 pm Early Preterm Infant Microbiome Impacts Adult Learning
Synopsis
- Preterm infant microbiome development
- Early preterm infant microbiome impacts adult learning
- Potential mechanisms-systemic inflammation and BBB
3:30 pm Translational Precision Probiotics: From Concept to Marketing
Synopsis
- ImmuneBiotics™, new probiotic products designed with pharmaceutical precision
- Translational success of GutMagnific® – a multi-targeted therapeutic microbial consortium – from the lab to the clinic and to the commercial market
- Clinical evaluation of GutMagnific® in patients with post-viral fatigue – a condition considered as a long-term effect of COVID-19